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longitudinal studies on the natural history of anal, penile, and oropharyngeal cancers.
The objective of this paper is the synthesis of the totality of evidence on anal, penile, 
and oropharyngeal cancers for the purpose of parameterizing decision analytic 
modeling. Following the known natural history of cervical carcinogenesis, our goal is 
to estimate the rates of transition from HPV infection to precancer, the rate of 
precancer clearance, and the rate of progression of precancer to cancer. METHODS:
We conducted a systematic review of the literature to identify all articles with longitu-
dinal data on the natural history of anal, penile, and oropharyngeal cancers. Including 
those studies that report quantiﬁ able evidence, we conduct a meta-analysis on the 
core parameters. The review was performed as per the methods recommended by 
the Cochrane Collaboration. RESULTS: Using PubMed, we identiﬁ ed 605 articles rel-
evant to the anal site, 540 articles for the penile site, and 267 on the oropharyngeal 
site. However, systematic review resulted in only 9 studies, all of which pertained to
anal precancer/cancer. Given the available data, we estimated the annual rates of pre-
cancer clearance and progression to be 11.4% (8.34%, 14.55%) and 2.18% (0.92%, 
3.47%), respectively. CONCLUSIONS: Decision analytic models provide a frame-
work for formulation of vaccination policies, incorporating all available evidence. This
review summarizes the totality of evidence on HPV and these three cancers to inform
health policy, speciﬁ cally policies concerning male vaccination against papillomavirus
(MVP).
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OBJECTIVES: Medical treatment for mRCC during 2002 represented around 4% of 
the resources designed for cancer treatment in Colombia; a local study has shown that
Sunitinib (SU) was the most cost-effective medication for ﬁ rst-line treatment of mRCC. 
We evaluated the budgetary impact of including SU as choice for ﬁ rst-line treatment
of mRCC compared to the current treatment being offered in Colombia (Interferon-á
(IFN), BevacizumabIFN and Sorafenib). METHODS: Sunitinib’s budgetary impact 
was estimated including mRCC patients which were candidates to receive ﬁ rst-line 
treatment under the SGSSS, using a 5-year time horizon. A Markov model was devel-
oped to predict costs simulating disease progression. Data regarding frequency of use
and health service cost units consumed was taken from a series of 24 patients treated
in four different cities. Service costs corresponded to the average value billed by the 
HMOs, calculated from 33 sources of information which were representative of the
country’s market. The 5-year projected proﬁ le for the current treatment of patients
suffering from mRCC was estimated starting from each medication’s market share 
and then compared to a scenario of changing Sunitinib’s share to being 100%. The
measures of effectiveness applicable for the projection were taken from previously-
published clinical trials. A One-way sensitivity analysis was conducted for validating
the model’s robustness and costs are shown in Colombian pesos (Col$) (Exchange rate 
1 USD  1966.26 Col$). RESULTS: The total budgetary impact of SU as ﬁ rst-line
treatment for mRCC represented a saving for the Colombian SGSSS of Col$
2,038,197,489 during 2009, Col$ 2,215,421,548 in 2010, Col$ 2,068,559,499 in 
2011, Col$ 1,923,678,137 in 2012 and Col$ 1,840,110,375 in 2013. This would 
represent an overall saving of Col$ 10,085,967,048 for the next 5-years. CONCLU-
SIONS: Including SU as the option of choice for ﬁ rst-line treatment of mRCC in the 
Colombian SGSSS would be favorable and cost-saving.
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OBJECTIVES: To assess the current literature on the cost-effectiveness of HPV DNA 
testing (HPVt) a) as an alternative to conventional cytology and b) to triage equivocal
cytology results. METHODS: Studies are included if they provide cost-effectiveness 
ﬁ gures for HPVt in relation to no screening or conventional cytology, are in English, 
based on a sample drawn from a developed market economy and were published after
2002. RESULTS: Eleven articles matching the search criterion were found. Though
time horizons and costs that are included vary, HPVt is generally found to be cost-
effective for older women. Based on a ﬁ ve year screening interval, using HPV DNA 
testing to triage atypical squamous cells of undetermined signiﬁ cance is estimated to
cost between about $2,900 to $33,000 per life year saved. CONCLUSIONS: HPVt 
may be a cost-effective screening tool for cervical cancer.
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OBJECTIVES: In current era the costs of the health keeping are increasing, therefore
the pharmacoeconomic has determing role. Analysis includes all stages of health 
keeping , but spotlights are drug costs. Selection of drugs according general criteria 
helps to save public ﬁ nance and allows it better utilization. METHODS: Valuation of 
utilization of drugs in oncological practice is based on data from the State Institute 
for Drug Control in Slovakia which have been evaluated for time period 10 years.
Data from the Public Health Insurance, which consist of drug costs, costs on diagnostic 
and therapy of oncological diseases, are attached to the former data. RESULTS: Public 
Health Insurance invested €0.19 mld on the therapy of the patients with oncological 
disease, which presented 10% from all costs on health keeping. Drugs represented
about 38% , hospitalization represented 28%, costs of diagnostic represented 15%
and ambulation health keeping represented 14%. But costs on ambulation health 
keeping have increased more than 28%, drug costs more than 15% and diagnostic 
costs more than 13%. According these data the most expensive diagnosis are breast 
cancer, colorectal cancer and the cancer of lungs. CONCLUSIONS: Health Insurances 
as ﬁ nancial institutions play the most important role in payment of complex therapy
of oncological patients. Because of new technology on diagnostic and therapy in 
oncology, economic value of costs is increasing. Costs of modern oncological therapy 
per one patient are more than approximately €1000.
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OBJECTIVES: There is a group of neoplasia that secretes vasoactive peptides causing
carcinoid syndrome. Surgical treatment is the election, however, if after surgery a
residual tumor is maintained, the use of somatostatin analogs: lanreotide Autogel y 
octreotide, is the treatment to follow. The objective of this research paper is to evaluate
which of the somatostatin analogs is the most effective in the symptomatic control of 
carcinoid syndrome, associated with the lowest cost. METHODS: Cost minimization
analysis from an institutional perspective was estimated, considering only direct
medical costs for a one year temporary horizon, using a decision tree model. Univariate 
sensitivity and probability analysis was carried out for this purpose. Costs were esti-
mated using prices of 2008 and are expressed in US dollars (exchange rate of 11.14
pesos/ 1 US dollar). RESULTS: According to the model, 41.3% of patients would
achieve control of their symptomatology either with Lanreotide Autogel, as with
octreotide, when adjusting the reported efﬁ cacy in the literature by the survival rate 
of one year for this illness. Treatment with Lanreotide Autogel implies the lowest 
average cost per patient with carcinoid syndrome: $15,317.18 followed by the treat-
ment with octreotide with a cost of $19,231.42. Sensitivity analyses show that lan-
reotide would support the treatment with the lowest cost, which would make it the 
dominant treatment or at least the treatment above the efﬁ ciency line. CONCLU-
SIONS: Lanreotide Autogel is the treatment that minimizes attention cost of carci-
noid syndrome, from the institutional perspective within the Mexican context.
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OBJECTIVES: Metastatic Renal cell carcinoma (mRCC), the most prevalent kidney 
cancer, is a rare malignancy with a poor prognosis; fewer than 10% of patients with 
metastatic disease survive beyond 5 years. The purpose of the study was to model the
economic and health consequences of ﬁ rst-line treatments in adult patients with mRCC 
in stages III and IV from an institutional perspective. METHODS: A cost-effectiveness 
analysis was developed using a stochastic Markov modeling approach. The model 
simulates treatment costs, progression free-months (PFM) and overall survival (OS) 
in a three-year period among four possible health states (no new progression, death 
due to mRCC, history of new progression and death due to other causes). The model 
compared in a six-week cycles: sunitinib 50 mg/day vs. sorafenib, bevacizumabIFN-
alpha and IFN-alpha alone (baseline). Transition probabilities were obtained from 
previously published trials. Resource use and costs data were obtained from random-
ized hospital records at Hospital de Oncologia CMN “Siglo XXI” in Mexico City 
(n  35). Both costs and effectiveness were discounted using a 3% annual rate. One-
way and probabilistic sensitivity analyses were performed and acceptability curves 
were constructed. RESULTS: First-line treatment with sunitinib showed the highest 
PFM and OS (10.1 and 19.9 months) followed by bevacizumabIFN-alpha (9.4 and 
19.1 months); sorafenib(5.1 and 17.3 months) and IFN-alpha alone(4.72 and 16.35 
months). Expected health care costs for sunitinib in the three-year follow-up period 
resulted in US$49,181; bevacizumabIFN-alpha (US$95,363); sorafenib (US$50,265) 
